Abstract
The recognition that malfunction of the microtubule (MT) associated protein tau is likely to play a defining role in the onset and/or progression of a number of neurodegenerative diseases, including Alzheimers disease, has resulted in the initiation of drug discovery programs that target this protein. Tau is an endogenous MT-stabilizing agent that is highly expressed in the axons of neurons. The MT-stabilizing function of tau is essential for the axonal transport of proteins, neurotransmitters and other cellular constituents. Under pathological conditions, tau misfolding and aggregation results in axonal transport deficits that appear to have deleterious consequences for the affected neurons, leading to synapse dysfunction and, ultimately, neuronal loss. This review focuses on both progress and unresolved issues surrounding the development of novel therapeutics for the treatment of neurodegenerative tauopathies, which are based on (A) MT-stabilizing agents to compensate for the loss of normal tau function and (B) small molecule inhibitors of tau aggregation.
Keywords: Protein-protein interaction, tau, Alzheimer's disease, neurodegenerative tauopathies, microtubule-stabilizing agents, aggregation inhibitors, microtubule, neuronal loss, cyclosporine A, FK506, taxanes, vinca alkaloids, RGD-mimetics, central nervous system, Pick's disease, frontotemporal dementia, neurofibrillary tangles, frontotemporal lobar degeneration, tau-MT complex, phosphorylation, antineoplastic agents, rheumatoid arthritis, psoriasis, paclitaxel, blood-brain barrier, P-glycoprotein, ATP-binding cassette, IDN5109, brain to plasma ratio, TXD258, Larotaxel, ANG1005, Angiopep-2, Epothilones, Ixabepilone, desoxyepothilones, discodermolide, dictyostatin, cyclostreptin, davunetide, N-methyl-D-aspartate, phenothiazines, anthraquinones, N-phenylamines, thiazolyl-hydrazides, rhodanines, quinoxalines, aminothienopyridazines
Current Topics in Medicinal Chemistry
Title: Modulation of Protein-Protein Interactions as a Therapeutic Strategy for the Treatment of Neurodegenerative Tauopathies
Volume: 11 Issue: 3
Author(s): C. Ballatore, K. R. Brunden, J. Q. Trojanowski, V. M.-Y. Lee, A. B. Smith and D. M. Huryn
Affiliation:
Keywords: Protein-protein interaction, tau, Alzheimer's disease, neurodegenerative tauopathies, microtubule-stabilizing agents, aggregation inhibitors, microtubule, neuronal loss, cyclosporine A, FK506, taxanes, vinca alkaloids, RGD-mimetics, central nervous system, Pick's disease, frontotemporal dementia, neurofibrillary tangles, frontotemporal lobar degeneration, tau-MT complex, phosphorylation, antineoplastic agents, rheumatoid arthritis, psoriasis, paclitaxel, blood-brain barrier, P-glycoprotein, ATP-binding cassette, IDN5109, brain to plasma ratio, TXD258, Larotaxel, ANG1005, Angiopep-2, Epothilones, Ixabepilone, desoxyepothilones, discodermolide, dictyostatin, cyclostreptin, davunetide, N-methyl-D-aspartate, phenothiazines, anthraquinones, N-phenylamines, thiazolyl-hydrazides, rhodanines, quinoxalines, aminothienopyridazines
Abstract: The recognition that malfunction of the microtubule (MT) associated protein tau is likely to play a defining role in the onset and/or progression of a number of neurodegenerative diseases, including Alzheimers disease, has resulted in the initiation of drug discovery programs that target this protein. Tau is an endogenous MT-stabilizing agent that is highly expressed in the axons of neurons. The MT-stabilizing function of tau is essential for the axonal transport of proteins, neurotransmitters and other cellular constituents. Under pathological conditions, tau misfolding and aggregation results in axonal transport deficits that appear to have deleterious consequences for the affected neurons, leading to synapse dysfunction and, ultimately, neuronal loss. This review focuses on both progress and unresolved issues surrounding the development of novel therapeutics for the treatment of neurodegenerative tauopathies, which are based on (A) MT-stabilizing agents to compensate for the loss of normal tau function and (B) small molecule inhibitors of tau aggregation.
Export Options
About this article
Cite this article as:
Ballatore C., R. Brunden K., Q. Trojanowski J., M.-Y. Lee V., B. Smith A. and M. Huryn D., Modulation of Protein-Protein Interactions as a Therapeutic Strategy for the Treatment of Neurodegenerative Tauopathies, Current Topics in Medicinal Chemistry 2011; 11 (3) . https://dx.doi.org/10.2174/156802611794072605
DOI https://dx.doi.org/10.2174/156802611794072605 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Remodelling of the Ca2+ Toolkit in Tumor Endothelium as a Crucial Responsible for the Resistance to Anticancer Therapies
Current Signal Transduction Therapy Neuroinflammation: A Therapeutic Target of Cotinine for the Treatment of Psychiatric Disorders?
Current Pharmaceutical Design α-Melanocyte Stimulating Hormone as a Potential Therapy for Alzheimer's Disease
Current Alzheimer Research Lipid Based Anti-Retroviral Nanocarriers: A Review of Current Literature and Ongoing Studies
Drug Delivery Letters The Potential Roles of Magnetic Resonance Spectroscopy and Perfusion- Weighted Imaging in the Grading of Cerebral Gliomas
Current Medical Imaging Biological and Chemical Diversity of Coral-Derived Microorganisms
Current Medicinal Chemistry Cancer Drug Discovery Targeting Histone Methyltransferases: An Update
Current Medicinal Chemistry In vivo Evaluation and Alzheimer’s Disease Treatment Outcome of siRNA Loaded Dual Targeting Drug Delivery System
Current Pharmaceutical Biotechnology Dendritic Cells and their Receptors in Antitumor Immune Response
Current Molecular Medicine Chondroitin Sulfate Glycosaminoglycans for CNS Homeostasis-Implications for Material Design
Current Medicinal Chemistry The Plasma Levels of hsa-miR-19b-3p, hsa-miR-125b-5p, and hsamiR- 320c in Patients with Asthma, COPD and Asthma-COPD Overlap Syndrome (ACOS)
MicroRNA The Application of lncRNAs in Cancer Treatment and Diagnosis
Recent Patents on Anti-Cancer Drug Discovery Protective Effect of Resveratrol against Glioblastoma: A Review
Anti-Cancer Agents in Medicinal Chemistry Adenovirus Mediated Herpes Simplex Virus-Thymidine Kinase/Ganciclovir Gene Therapy for Resectable Malignant Glioma
Current Gene Therapy Editorial (Thematic Issue: Role of Antioxidants Treatments on Oxidative Stress and Calcium Entry in Neurological Disease: Focus on TRP Channels)
Current Neuropharmacology Infringement of the Barriers of Cancer Via Dietary Phytoconstituents Capsaicin Through Novel Drug Delivery System
Current Drug Delivery P2Y Receptor Activation Affects the Proliferation and Differentiation of Glial and Neuronal Cells: A Focus on Rat C6 Glioma Cells
Current Neuropharmacology Expanding Spectrum of Sodium Potassium Chloride Co-transporters in the Pathophysiology of Diseases
Current Neuropharmacology MICA Molecules in Disease and Transplantation, a Double-Edged Sword?
Current Immunology Reviews (Discontinued) Post-Translational Modifications of PTEN and their Potential Therapeutic Implications
Current Cancer Drug Targets